Loading
A phase 1/2 trial of N17350 in melanoma, head and neck squamous cell carcinoma and non-small-cell lung cancer, run by Onchilles Pharma Inc, now recruiting.
Intratumoral N17350 in Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT07339176 by Onchilles Pharma Inc, with 275 participants planned, started 2026-05-25 and due to reach its primary completion in 2028-07. Interventions recorded: N17350.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Melanoma and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Non-small-cell lung cancer and the tag pipeline.
Shares Melanoma, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/